By Counterforce Health Team in Brensocatib (BRINSUPRI) —

How to Get Brensocatib (BRINSUPRI) Covered by Humana in New Jersey: Prior Authorization, Appeals, and Medical Necessity Requirements

Answer Box: Getting Brensocatib (BRINSUPRI) Covered by Humana in New Jersey

Brensocatib (BRINSUPRI) requires prior authorization from Humana for non-cystic fibrosis bronchiectasis patients ≥12 years old. Submit PA via Humana provider portal with CT scan confirmation, pulmonologist consultation, and documentation of ≥2 exacerbations (adults) or ≥1 (pediatrics) in the past year. If denied, you have 65 days to appeal internally, followed by automatic external review through New Jersey's Independent Health Care Appeals Program (IHCAP) via Maximus Federal Services at no cost.

First step today: Contact your prescriber to submit the PA request with required clinical documentation to avoid delays.

Table of Contents

  1. Humana's Coverage Policy Overview
  2. FDA Indication Requirements
  3. Step Therapy & Medical Exceptions
  4. Quantity Limits & Renewal Requirements
  5. Required Diagnostics & Documentation
  6. Site of Care & Specialty Pharmacy Rules
  7. Evidence for Medical Necessity
  8. Sample Medical Necessity Letter
  9. Appeals Process in New Jersey
  10. Common Denial Reasons & Solutions
  11. Costs & Patient Support Options
  12. FAQ

Humana's Coverage Policy Overview

Humana covers Brensocatib (BRINSUPRI) under Medicare Advantage and Part D plans with prior authorization requirements. The medication is included on Humana formularies but requires clinical justification due to its high cost (approximately $88,000 annually) and new-to-market status.

Plan Types Affected:

  • Medicare Advantage (Part C)
  • Medicare Part D prescription drug plans
  • Some commercial plans (verify specific coverage)

Key Policy Points:

  • Prior authorization mandatory for all new starts
  • Renewal required every 6-12 months
  • Specialty drug tier placement likely
  • Medical necessity review by Humana Clinical Pharmacy Review (HCPR)

FDA Indication Requirements

Brensocatib received FDA approval in August 2025 as the first treatment specifically for non-cystic fibrosis bronchiectasis (NCFB).

Coverage Requirements

Requirement Details Documentation Needed
Age ≥12 years old Birth date verification
Diagnosis NCFB confirmed by CT imaging ICD-10 codes J47.0, J47.1, or J47.9
Exacerbation History ≥2 in past 12 months (adults), ≥1 (pediatrics) Clinical notes, hospitalization records
Specialist Consultation Pulmonologist or infectious disease physician Prescriber credentials verification
CF Exclusion Rule out cystic fibrosis Genetic testing if indicated

Dosing Options: 10 mg or 25 mg once daily tablets. The FDA prescribing information doesn't specify dose selection criteria, leaving this to clinical judgment.

Step Therapy & Medical Exceptions

While Humana's specific step therapy requirements for Brensocatib aren't publicly detailed, expect requirements for prior standard-of-care treatments based on typical specialty drug protocols.

Likely Required Prior Treatments:

  • Macrolide antibiotics (azithromycin, erythromycin) for exacerbation reduction
  • Airway clearance therapy (chest physiotherapy, oscillatory devices)
  • Bronchodilators for symptom management
  • Mucolytics (hypertonic saline, dornase alfa if indicated)

Medical Exception Pathways:

  • Contraindications to standard therapies
  • Treatment failures with documented lack of efficacy
  • Intolerance to required medications
  • Clinical urgency due to rapidly declining lung function
Tip: Document specific reasons why standard treatments failed, including dates, dosages, and clinical response to strengthen your exception request.

Quantity Limits & Renewal Requirements

Humana applies quantity limits to control utilization and costs for specialty medications.

Expected Limits:

  • Initial approval: 30-90 day supply
  • Quantity: Aligned with FDA dosing (one tablet daily)
  • Refill restrictions: May require prescriber confirmation for early refills

Renewal Process:

Submit renewal requests 30-60 days before expiration via:

Required Renewal Documentation:

  • Treatment response assessment
  • Adherence confirmation (≥85%)
  • Continued medical necessity
  • Updated pulmonary function tests
  • Specialist evaluation

Required Diagnostics & Documentation

Essential Clinical Evidence:

Imaging Requirements:

  • High-resolution CT (HRCT) showing bronchial dilation
  • Radiologist interpretation confirming bronchiectasis
  • Images within past 2 years (verify with plan)

Pulmonary Function:

  • Baseline FEV1/FVC measurements
  • Serial testing to document decline or stability
  • Post-bronchodilator values preferred

Laboratory Work:

  • Sputum cultures if available
  • Inflammatory markers (CRP, ESR) during exacerbations
  • Immunoglobulin levels if immunodeficiency suspected

Clinical Documentation:

  • Detailed exacerbation history with dates
  • Symptom severity scores (if available)
  • Prior treatment responses and failures
  • Current medication regimen

Site of Care & Specialty Pharmacy Rules

Based on available information, Brensocatib doesn't require specific site-of-care restrictions as it's an oral medication.

Pharmacy Options:

  • Retail specialty pharmacies in Humana network
  • Mail-order pharmacy for 90-day supplies
  • Local pharmacies (may require special ordering)

Important: Verify current network pharmacy requirements with Humana, as specialty drug routing can change.

Prescriber Requirements:

Evidence for Medical Necessity

Clinical Trial Data:

Reference the ASPEN phase 3 trial showing:

  • 25% reduction in exacerbation rate vs. placebo
  • Improved lung function (FEV1) with 25 mg dose
  • Better quality of life scores
  • Safety profile supporting long-term use

Supporting Guidelines:

  • FDA prescribing information
  • Bronchiectasis management guidelines from relevant medical societies
  • Peer-reviewed literature on NCFB treatment

Patient-Specific Factors:

  • Exacerbation frequency and severity
  • Impact on daily functioning
  • Response to previous treatments
  • Comorbidity considerations

Sample Medical Necessity Letter

Template Paragraph Structure:

"[Patient name] is a [age]-year-old with non-cystic fibrosis bronchiectasis confirmed by HRCT on [date], showing [specific findings]. Over the past 12 months, they have experienced [number] pulmonary exacerbations requiring [treatments]. Despite trials of [prior therapies with dates and outcomes], their condition remains poorly controlled with [current symptoms/limitations]. Brensocatib represents the first FDA-approved therapy specifically for NCFB and is medically necessary to reduce exacerbation frequency and preserve lung function based on ASPEN trial data showing 25% exacerbation reduction. The requested 25 mg daily dose aligns with FDA prescribing guidelines and will be monitored through regular pulmonary function testing and specialist follow-up."

Appeals Process in New Jersey

Internal Appeal Timeline:

  • Filing deadline: 65 days from denial notice
  • Humana decision: 30 days (Part C), 7 days (Part D)
  • Expedited option: 72 hours for urgent cases

External Review (IHCAP):

New Jersey's Independent Health Care Appeals Program provides automatic external review through Maximus Federal Services.

Process:

  1. Automatic referral after internal denial
  2. Preliminary review: 5 business days
  3. Full review: 45 days standard, expedited available
  4. Cost: Free to patients
  5. Decision: Binding on Humana if overturned

Contact Information:

  • IHCAP Hotline: 1-888-393-1062
  • NJ DOBI Consumer Hotline: 1-800-446-7467

Required Appeal Documents:

  • Copy of denial letter
  • Medical necessity letter from prescriber
  • Clinical documentation and test results
  • Patient impact statement
  • Prior treatment history

Common Denial Reasons & Solutions

Denial Reason Solution Strategy
"Not medically necessary" Submit comprehensive clinical documentation with ASPEN trial references
"Experimental/investigational" Emphasize FDA approval status and first-in-class designation
"Step therapy required" Document failures/contraindications to macrolides and standard care
"Quantity exceeds limits" Provide dosing justification from prescribing information
"Non-formulary" Request formulary exception with medical necessity letter

Costs & Patient Support Options

Manufacturer Support:

  • BRINSUPRI inLighten Program: Patient support services
  • Copay assistance: Check eligibility at brinsupri.com
  • Prior authorization support: Available through manufacturer

Additional Resources:

  • Patient advocacy organizations
  • State pharmaceutical assistance programs
  • Foundation grants for qualifying patients
Note: Counterforce Health helps patients and providers navigate complex prior authorization requirements and turn denials into successful appeals. Our platform analyzes denial letters and creates targeted, evidence-based responses aligned with payer policies. Learn more about our services.

FAQ

How long does Humana prior authorization take for Brensocatib? Standard processing is 7-30 days depending on plan type. Expedited reviews available for urgent cases within 72 hours.

What if Brensocatib is non-formulary on my Humana plan? Request a formulary exception with medical necessity documentation. Success rates improve with comprehensive clinical justification.

Can I request an expedited appeal in New Jersey? Yes, both internal (Humana) and external (IHCAP) processes offer expedited options when delays could jeopardize health.

Does step therapy apply if I failed treatments outside New Jersey? Prior treatment history from any state should count. Provide documentation of treatments tried and outcomes.

What happens if my appeal is denied at all levels? Medicare beneficiaries can escalate to Administrative Law Judge (ALJ) review if the amount in controversy meets minimum thresholds.

How often do I need to renew approval? Initial approvals typically last 6 months, with subsequent renewals potentially extending to 12 months based on stability.

Sources & Further Reading

This information is for educational purposes only and does not constitute medical or legal advice. Always consult with your healthcare provider and insurance plan for specific coverage decisions. For additional help navigating insurance approvals and appeals, Counterforce Health specializes in turning prescription drug denials into successful approvals through evidence-based appeal strategies.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.